Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
(Adnkronos) – BRENTWOOD, Tenn., Oct. 18, 2023 /PRNewswire/ — Currax Pharmaceuticals LLC (“Currax”) today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the cardiovascular safety of CONTRAVE®/MYSIMBA®, a
